Αρχική World News Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with... World News Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Από Ogkologos - 22 Ιανουαρίου, 2025 729 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of... 21 Μαρτίου, 2023 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... 6 Μαΐου, 2025 Combination of Azacitidine and Venetoclax in Previously Untreated AML 18 Αυγούστου, 2020 ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC 23 Νοεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking New reports show staff shortages continue to hold back cancer care EMA recommends granting a marketing authorisation for daraxonrasib Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial